Osteoporosis in Family Practice

Journal of the Pakistan Medical Association

Volumn 53, Issue 9, 2003, Pages 433-436

  Usman, J ^a   Siddiqui, H ^a  

^a ZIAUDDIN MEDICAL UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CYCLOSPORIN; ETIDRONIC ACID; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; METHOTREXATE; PHENOBARBITAL; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STATINE DERIVATIVE; THYROID HORMONE; VITAMIN D; ZOLEDRONIC ACID;

ACROMEGALY; AMENORRHEA; ANOREXIA NERVOSA; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; FEMALE; GENERAL PRACTICE; HEMOCHROMATOSIS; HUMAN; HYPERADRENOCORTICISM; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; META ANALYSIS; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; REVIEW; SCREENING; THYROTOXICOSIS;

FAMILY PRACTICE; FEMALE; HUMANS; MALE; OSTEOPOROSIS;

EID: 0142121301     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Noun B, Louba L. What was the disease of the bone that affected King David. J Gerontology 2002;57:M152-4.
2. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
3. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000;27:585-90.
4. Biskobing DM. COPD and osteoporosis. Chest 2002;121:609-10.
5. Compston J. The effect of liver disease on bone. In: McIntyre, Benhamou JP, Bircher J, et al. (ed). Oxford textbook of hepatology. Oxford: University Press, 1991.
6. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
7. Estell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736-46.
8. World Health Organization. Study group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO 1994.
9. Marshall D, Jonhell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
10. Jack SD. Mineral and Metabolic Bone Disease. Washington Manual of Medical Therapeutics. 1998. 29th ed.Philadelphia: Lippincot - Raven 1998, pp. 450-51.
11. Harper KD, Weber TJ. Secondary osteoporosis: diagnostic considerations. Endocrinol Metab Clin North Am 1998;27:325-48.
12. Goldstein MF, Fallon JJ, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest., 1999;116: 1733-49.
13. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50:11-19.
14. Tresolni CP, Gold DT, Lee LS (eds). Working with patents to prevent, treat and manage osteoporosis: a curriculum guide for health professionals. 2nd ed.San Francisco: National Fund for Medical Education, 1998.
15. Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am 1998;27:255-65.
16. Daniel HW. Osteoporosis of the slender smoker. Arch Intern Med 1976;136:298-304.
17. Taxel P. Osteoporosis: detection, prevention and treatment in primary care. Geriatrics 1998;53:22-33.
18. National Osteoporotic Foundation, 1996 and 2015 osteoporosis prevalence figures: state-by-state report. January 1997. Women's Health Matters 1998;2:1.
19. Pakistan Medical Research Council. National Health Survey of Pakistan. Islamabad: PMRC 1998.
20. Habiba U, Ahmad S, Hassan L. Predisposition to osteoporosis in postmenopausal women. J Coll Physicians Surg Pak 2002;12:297-301.
21. Kroger H, Reeve J. Diagnosis of osteoporosis in clinical practice. Ann Med 1998;30:278-87.
22. Blake GM, Fogelman I. Applications of bone densitometry for osteoporosis. Endocrinol Metab Clin North Am 1998;27:267-88.
23. U.S Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams and Wilkins, 1996, pp. 1-28.
24. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, D.C: the Foundation, 1998, pp. 1-2.
25. Reid IR. The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998;27:389-98.
26. Pasco JA, Kotowicz MA, Henry M, et al. Statin Use, BMD and fracture risk: GEELONG osteoporosis study. Arch Intern Med 2002;162:537-40.
27. Dalsky GP, Stocke KS, Ehsani AA, et al. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 1988;108:824-28.
28. Henderson NK, White CP, Eisman JA. The role of exercise and fall risk reduction in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998;27:369-87.
29. Bourjeily G, Rochester CL. Exercise training in chronic obstructive pulmonary disease. Clin Chest Med 2000;21:763-81.
30. McClung MR, Spencer K. Non-pharmacological therapy for osteoporosis. In: Rosen CJ, (ed.) Osteoporosis: diagnosis and therapeutic principles. Totowa, NJ: Humana Press 1996, pp. 189-99.
31. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
32. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA 2001;285:1415-18.
33. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
34. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998; 27:349-67.
35. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonodal men. J Clin Endocrinl Metab 2000;85:2670-7.
36. Clemett D, Spender CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379-411.
37. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of Raloxifene for the Prevention and treatment of postmenopausal osteoprosis. Endocr Rev 2002;23:524-28.
38. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoprosis. Endocr Rev 2002;23:540-51.
39. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, D.C: the Foundation 1998, pp. 1-2.
40. Wang WQ, Ip MS, Tsang KW, et al. Antiresorptive therapy in asthmatic patients receiving high dose inhaled steroids: a prospective study for 18 months. J Allergy Clin Immunol 1998;101:445-50.
41. Cranney A, Wells G, William A. Meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:508-16.
42. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of therapeutics for post-menopausal osteoporosis. Endocr Rev 2002;23:517-23.
43. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
44. Reid IR. Therapy of osteoporosis: calcium, vitamin D, and exercise. Am J Med Sci 1996;312:278-86.
45. Task Force on osteoporosis guidelines. American College of Rheumatology. Arthritis Rheum 1996;39:1791-1801.
46. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA 2001;285:1415-18.
47. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998;27:349-67.
48. Jeanette E. Evaluation and assessment of osteoporosis. Am Fam Physician 2001;63:897-904.